new glp-1 drugs Popular medications may have health benefits that extend beyond weight loss and blood sugar control, a study finds Eli Lilly to seek approval

If a peptide reconstitution looks clear on day 1 but cloudy by day 4-5, sterile-instead-of-bacteriostatic is one of the most-documented causes

article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)

Clinical administration of MSCs in CKD Although many pre-clinical studies have suggested that MSCs may have a broad application prospect to improve renal function [19,20,21,22], it is still uncertain about the specific effect in clinical utilization

Glutathione is evaluated in laboratory research to study redox balance and oxidative stress pathway research